Virax Biolabs
VRAX
5 hedge funds and large institutions have $424K invested in Virax Biolabs in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, reducing their positions, and 4 closing their positions.
418% more capital invested
Capital invested by funds: $81.8K → $424K (+$342K)
0.08% more ownership
Funds ownership: 0.12% → 0.2% (+0.08%)
29% less funds holding
Funds holding: 7 → 5 (-2)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$309K |
| 2 |
Squarepoint
New York
|
+$93.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$34.3K |
| 4 |
Jane Street
New York
|
+$26.7K |
| 5 |
HT
Headlands Technologies
Chicago,
Illinois
|
+$287 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$33K |
| 2 |
HF
HRT Financial
New York
|
-$29K |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$348 |
| 4 |
Wells Fargo
San Francisco,
California
|
-$116 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Renaissance Technologies
New York
| $282K | +$309K | +5,376 | +1,222% |
|
|
2
Squarepoint
New York
| $78.8K | +$93.4K | +1,625 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $39.8K | +$34.3K | +597 | +267% |
|
|
4
Jane Street
New York
| $22.6K | +$26.7K | +465 | New |
|
|
HT
5
Headlands Technologies
Chicago,
Illinois
| $359 | +$287 | +5 | +250% |
|
|
VF
6
Virtu Financial
New York
| – | -$33K | -1,122 | Closed |
|
|
HF
7
HRT Financial
New York
| – | -$29K | -1,027 | Closed |
|
|
8
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$348 | -12 | Closed |
|
|
9
Wells Fargo
San Francisco,
California
| – | -$116 | -4 | Closed |
|
VRAX Hedge Fund Activity: Q3 2024 in Review
5 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Virax Biolabs (VRAX) for Q3 2024, worth a combined $424K — up 418% from $81.8K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of VRAX and 2 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 3 added.
The largest buyer was Renaissance Technologies, adding an estimated $309K. The largest seller was Virtu Financial, exiting entirely with an estimated $33K sold.
- 5 institutional investors held Virax Biolabs (VRAX) as of Q3 2024, down from 7 in Q2 2024.
- Funds reported $424K of Virax Biolabs stock for Q3 2024, up 418% quarter-over-quarter.
- 2 funds opened new Virax Biolabs positions in Q3 2024 and 4 closed out, a net change of -2 holders.
- The largest Virax Biolabs buyer in Q3 2024 was Renaissance Technologies, an estimated $309K added.
- The largest Virax Biolabs seller in Q3 2024 was Virtu Financial, an estimated $33K sold.
Based on aggregated 13F filings for Q3 2024.